News related to the ongoing COVID-19 pandemic with focus on the Nordic life science industry.
Updated on a regular basis.
Research by an international consortium involving researchers at Karolinska Institutet shows that more than 10 percent of young and previously healthy people who develop severe COVID-19 have misguided antibodies that
“We are holding our breath,” is how one company described the situation for the life science industry due to the economic effects of COVID-19. This was in April; now Autumn
SynAct Pharma has announced the initiation of a Phase II clinical study to evaluate the safety and efficacy of the company’s lead candidate drug AP1189 in adults diagnosed with COVID-19
In a new study published in JAMA researchers at Karolinska Institutet and Karolinska University Hospital have examined the association between a positive SARS-CoV-2 test during pregnancy and complications in mothers
Clinical trials for the AstraZeneca Oxford coronavirus vaccine, AZD1222, have resumed in the UK following confirmation by the Medicines Health Regulatory Authority (MHRA) that it was safe to do so.
Pfizer and BioNTech have had concluded exploratory talks with the European Commission for a proposed supply of 200 million doses of their investigational BNT162 mRNA-based vaccine candidate against SARS-CoV-2 to
The Phase III clinical trials for a coronavirus vaccine, developed by AstraZeneca and Oxford University, have been paused after a participant had an adverse reaction in the UK. As part
Nine leading US and European vaccine developers have signed a pledge to continue to make the safety and well-being of vaccinated individuals the top priority in development of the first
Researchers at Karolinska Institutet and Science for Life Laboratory in Sweden and Tor Vergata University of Rome in Italy have mapped the immune response in children affected by a rare
Researchers at Karolinska Institutet have identified a small neutralizing antibody, a so-called nanobody, that has the capacity to block SARS-CoV-2 from entering human cells. The researchers believe this nanobody has
Scientists at deCODE genetics in Iceland, a subsidiary of Amgen, and their collaborators, have published a study in The New England Journal of Medicine, that shows that antiviral antibodies against
Oncology Venture has announced that its PARP inhibitor Stenoparib (formerly known as 2X-121) has shown in vitro anti-viral activity against Coronavirus in pre-clinical studies. The studies were conducted at the
AstraZeneca is issuing a commitment to the highest safety standards and to broad and equitable access around the world for its COVID-19 vaccine AZD1222, it states. Follow the science and
Development of AstraZeneca’s COVID-19 vaccine AZD1222 expands into US Phase III clinical trial across all adult age groups. The US trial, called D8110C00001, is funded by the Biomedical Advanced Development
Biotech company Indoor Biotechnologies, co-founded by a Cardiff University alumnus, has developed a test for coronavirus T cells which can potentially provide longer-term immunity to the virus than antibodies. The
The Nordic countries have handled the COVID-19 pandemic differently in many aspects and learning from each other would hopefully benefit our preparedness for another pandemic. As previously reported, given the similarity